| Hello EPPIC Global community,
We invite your participation to this exciting event by EPPIC Global, on The Story of Remdesivir: Discovery, Development, and Regulatory Approval for the Treatment of COVID-19.
Would you like to hear a first-person account from the 2 eminent scientists of Gilead Sciences, Richard Mackman, VP of Medicinal Chemistry and Yurong Lai, Sr Director of Drug Metabolism who were closely involved in the discovery and development of Remdesivir, the first antiviral approved by FDA in Oct’20 for treatment of CoV-2 infection. Come join us on 23rd Jan’21 from 3:00PM-4:30PM PDT to meet with these incredible folks in a Q&A session moderated by Sandhya Mandlekar.
The audience will get to learn all about the introduction to nucleoside agents, the mechanism of target inhibition and insights into the drug discovery campaign that eventually led to remdesivir. They will also go over the in vitro and in vivo ADME properties, the animal model efficacy data of remdesivir, clinical data, including remdesivir pharmacokinetics and efficacy, clinical pharmacology, drug-drug interaction potential and much more!
Register and join us to learn more. |
